CARTs targeting CD19 have also induced sustained antitumor immune responses in patients with B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)11, although the response rates vary for different disease subtypes12–14. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.